Miguel Sampayo-Cordero

5PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Antonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló

|Jul 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany

|Sep 27, 2022
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.

Joan Albanell, José Manuel Pérez-García, Miguel Gil-Gil

|Aug 11, 2021
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.

Alexander H G Paterson, Peter C Lucas, Stewart J Anderson

|Oct 23, 2019
Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.

Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Almudena Pardo-Mateos

Pageof 1

Frequent Collaborators

3 joint publications

Antonio Llombart-Cussac

3 joint publications

Javier Cortés

3 joint publications

Manuel Ruíz-Borrego

2 joint publications

Jose Pérez-García